Dr. Mirko Stange joined Ventac Partners as a Partner in January of 2008 in the firm’s Munich office. Through several years work experience as strategy consultant he has acquired considerable skills and expertise in the fields of growth and turn around strategies, manufacture and supply process optimization as well as risk financing and M&A processes. In this capacity he also serves as Head of Production at HumanAutoCell GmbH, a German therapeutic startup company developing a novel treatment for endstage liver disease.
Prior to joining Ventac Partners, Dr. Mirko Stange was during 2003-05 strategy consultant at McKinsey and subsequently with Droege & Comp. where he worked for clients across the Pharma, Biotech and Chemistry industries. As a team and project leader for international projects he has built a track record regarding successful implementation of operational excellence as well as identifying and evaluating business opportunities in startup, small- and large-cap companies.
Dr. Mirko Stange holds a Ph.D. degree in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill. His research focused on the molecular mechanisms underlying ischemic heart disease and received multiple honors including a fellowship award by the American Heart Association. In addition, Dr. Mirko Stange holds a M.S. degree in Chemistry from the Heinrich-Heine-University Düsseldorf, German